| Literature DB >> 3801271 |
K Ono, C Komuro, K Tsutsui, Y Shibamoto, T Nishidai, M Takahashi, M Abe, D C Shrieve.
Abstract
Two and four treatments of 5 mmol kg-1 of buthionine sulfoximine (BSO) at an interval of 12 h depleted the glutathione (GSH) content in NFSa tumours of C3H/He mice, respectively, to 24.0 and 1.78 percent of the untreated controls. BSO pre-treatments every 12 h enhanced the cytotoxicity of cyclophosphamide (CYC) towards artificial lung micrometastases of NFSa tumours giving enhancement ratios (ERs) ranging from 1.75 to 1.83 and from 2.41 to 2.73, for two and four BSO pretreatments respectively. Large ERs were obtained at low CYC doses (high cell survival). Four BSO pre-treatments at an interval of 12 h did not increase the cytotoxicity of CYC to bone marrow stem cells. Our results suggest a clinical applicability of the combination of BSO and CYC.Entities:
Mesh：
Substances：
Year: 1986 PMID： 3801271 PMCID： PMC2001553 DOI： 10.1038/bjc.1986.236
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640